207 related articles for article (PubMed ID: 37457690)
1. The actions of methotrexate on endothelial cells are dependent on the shear stress-induced regulation of one carbon metabolism.
Lang MB; Leung KY; Greene NDE; Malone KM; Saginc G; Randi AM; Kiprianos A; Maughan RT; Pericleous C; Mason JC
Front Immunol; 2023; 14():1209490. PubMed ID: 37457690
[TBL] [Abstract][Full Text] [Related]
2. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis.
Shea B; Swinden MV; Tanjong Ghogomu E; Ortiz Z; Katchamart W; Rader T; Bombardier C; Wells GA; Tugwell P
Cochrane Database Syst Rev; 2013 May; 2013(5):CD000951. PubMed ID: 23728635
[TBL] [Abstract][Full Text] [Related]
3. Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review.
Whittle SL; Hughes RA
Rheumatology (Oxford); 2004 Mar; 43(3):267-71. PubMed ID: 14963199
[TBL] [Abstract][Full Text] [Related]
4. Homocysteine and folate status in methotrexate-treated patients with rheumatoid arthritis.
van Ede AE; Laan RF; Blom HJ; Boers GH; Haagsma CJ; Thomas CM; De Boo TM; van de Putte LB
Rheumatology (Oxford); 2002 Jun; 41(6):658-65. PubMed ID: 12048292
[TBL] [Abstract][Full Text] [Related]
5. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis.
Shea B; Swinden MV; Ghogomu ET; Ortiz Z; Katchamart W; Rader T; Bombardier C; Wells GA; Tugwell P
J Rheumatol; 2014 Jun; 41(6):1049-60. PubMed ID: 24737913
[TBL] [Abstract][Full Text] [Related]
6. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis.
Ortiz Z; Shea B; Suarez Almazor M; Moher D; Wells G; Tugwell P
Cochrane Database Syst Rev; 2000; (2):CD000951. PubMed ID: 10796393
[TBL] [Abstract][Full Text] [Related]
7. [Reducing toxicity of methotrexate with folic acid].
Harten P
Z Rheumatol; 2005 Jun; 64(5):353-8. PubMed ID: 15965822
[TBL] [Abstract][Full Text] [Related]
8. Folate supplementation during methotrexate therapy for rheumatoid arthritis.
Morgan SL; Baggott JE
Clin Exp Rheumatol; 2010; 28(5 Suppl 61):S102-9. PubMed ID: 21044441
[TBL] [Abstract][Full Text] [Related]
9. Methotrexate-mediated activation of an AMPK-CREB-dependent pathway: a novel mechanism for vascular protection in chronic systemic inflammation.
Thornton CC; Al-Rashed F; Calay D; Birdsey GM; Bauer A; Mylroie H; Morley BJ; Randi AM; Haskard DO; Boyle JJ; Mason JC
Ann Rheum Dis; 2016 Feb; 75(2):439-48. PubMed ID: 25575725
[TBL] [Abstract][Full Text] [Related]
10. Folate Supplementation for Methotrexate Therapy in Patients With Rheumatoid Arthritis: A Systematic Review.
Liu L; Liu S; Wang C; Guan W; Zhang Y; Hu W; Zhang L; He Y; Lu J; Li T; Liu X; Xuan Y; Wang P
J Clin Rheumatol; 2019 Aug; 25(5):197-202. PubMed ID: 29975207
[TBL] [Abstract][Full Text] [Related]
11. Methotrexate normalizes up-regulated folate pathway genes in rheumatoid arthritis.
Blits M; Jansen G; Assaraf YG; van de Wiel MA; Lems WF; Nurmohamed MT; van Schaardenburg D; Voskuyl AE; Wolbink GJ; Vosslamber S; Verweij CL
Arthritis Rheum; 2013 Nov; 65(11):2791-802. PubMed ID: 23897011
[TBL] [Abstract][Full Text] [Related]
12. Methotrexate improves endothelial function in early rheumatoid arthritis patients after 3 months of treatment.
Cafaro G; Petito E; Bistoni O; Falcinelli E; Cipriani S; Borghi MC; Bonifacio AF; Giglio E; Alunno A; Perricone C; Gerli R; Gresele P; Bartoloni E
Arthritis Res Ther; 2022 Oct; 24(1):236. PubMed ID: 36280849
[TBL] [Abstract][Full Text] [Related]
13. Antirheumatic treatment is associated with reduced serum Syndecan-1 in Rheumatoid Arthritis.
Deyab G; Reine TM; Vuong TT; Jenssen T; Hjeltnes G; Agewall S; Mikkelsen K; Førre Ø; Fagerland MW; Kolset SO; Hollan I
PLoS One; 2021; 16(7):e0253247. PubMed ID: 34242246
[TBL] [Abstract][Full Text] [Related]
14. Effect of genetic polymorphisms in the folate pathway on methotrexate therapy in rheumatic diseases.
Stamp LK; Roberts RL
Pharmacogenomics; 2011 Oct; 12(10):1449-63. PubMed ID: 22008049
[TBL] [Abstract][Full Text] [Related]
15. Methotrexate: Implications of pharmacogenetics in the treatment of patients with Rheumatoid Arthritis.
Torres RP; Santos FP; Branco JC
ARP Rheumatol; 2022 Oct; 1(3):225-229. PubMed ID: 35724450
[TBL] [Abstract][Full Text] [Related]
16. Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study.
van Ede AE; Laan RF; Rood MJ; Huizinga TW; van de Laar MA; van Denderen CJ; Westgeest TA; Romme TC; de Rooij DJ; Jacobs MJ; de Boo TM; van der Wilt GJ; Severens JL; Hartman M; Krabbe PF; Dijkmans BA; Breedveld FC; van de Putte LB
Arthritis Rheum; 2001 Jul; 44(7):1515-24. PubMed ID: 11465701
[TBL] [Abstract][Full Text] [Related]
17. Methotrexate-induced cytotoxicity and genotoxicity in germ cells of mice: intervention of folic and folinic acid.
Padmanabhan S; Tripathi DN; Vikram A; Ramarao P; Jena GB
Mutat Res; 2009 Feb; 673(1):43-52. PubMed ID: 19110071
[TBL] [Abstract][Full Text] [Related]
18. Methotrexate and anti-tumor necrosis factor treatment improves endothelial function in patients with inflammatory arthritis.
Deyab G; Hokstad I; Whist JE; Smastuen MC; Agewall S; Lyberg T; Ronda N; Mikkelsen K; Hjeltnes G; Hollan I
Arthritis Res Ther; 2017 Oct; 19(1):232. PubMed ID: 29041979
[TBL] [Abstract][Full Text] [Related]
19. Modulation of orphan nuclear receptor NURR1 expression by methotrexate in human inflammatory joint disease involves adenosine A2A receptor-mediated responses.
Ralph JA; McEvoy AN; Kane D; Bresnihan B; FitzGerald O; Murphy EP
J Immunol; 2005 Jul; 175(1):555-65. PubMed ID: 15972692
[TBL] [Abstract][Full Text] [Related]
20. The influence of methotrexate on the gene expression of the pro-inflammatory cytokine IL-12A in the therapy of rheumatoid arthritis.
Hobl EL; Mader RM; Erlacher L; Duhm B; Mustak M; Bröll H; Högger P; Kalipciyan M; Jilma B
Clin Exp Rheumatol; 2011; 29(6):963-9. PubMed ID: 22133036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
